BAT 2024 Results Summary: New Business Earnings Growth,Despite 5.2% Revenue Decline

Apr.18.2025
BAT 2024 Results Summary: New Business Earnings Growth,Despite 5.2% Revenue Decline
Despite a 5.2% drop in reported revenue in 2024, BAT's organic revenue increased 1.3%, with new tobacco business profits.

Key points:

Performance in 2024: Despite a 5.2% decrease in reported revenue, organic revenue increased by 1.3%. The new tobacco business achieved profitability two years ahead of schedule, contributing an additional £2.51 billion in growth.

Progress of new tobacco products: The global number of adult users of new tobacco products has reached 29.1 million, accounting for 17.5% of company revenue.

Progress in harm reduction strategy: Continuing to advance the "Omni™ Declaration" and responsible product development, emphasizing collaboration with regulatory agencies.

Projected for 2025: Focus on execution and deployment, with expected annual revenue growth of 1% and profit growth of 1.5-2.5%; the second half of the year will be the main driver of growth.

Sustainable Development Goals: Reduce harm, climate, nature, recycling, community.

Board Changes: Soraya Benchikh appointed as Chief Financial Officer, Uta Kemmerich-Keil appointed as Independent Director.


On April 16, British American Tobacco (BAT) held its annual shareholders' meeting for the year 2025, where the BAT chairman provided a systematic summary of the company's operating results in 2024 and outlook for 2025, reaffirming their strategic direction towards a "smoke-free world." In 2024, which was a year for investment deployment, the group's financial performance met initial expectations. 

 

With reported exchange rates, the group's total revenue decreased by 5.2% year-on-year; however, it grew by 1.3% on a constant currency and organic basis. Adjusted organic operating profit increased by 1.4%, with a cash conversion rate of 101%. In particular, the new category tobacco business achieved adjusted growth of £251 million at constant exchange rates, with a category profit margin of 7.1%.

 

BAT stated that the overall performance showed the business resilience and employee execution ability. The new tobacco business achieved profitability two years ahead of schedule, marking a key milestone in the transformation process.

 

 

Become a primarily smoke-free enterprise by 2035, and to promote the establishment of industry standards

 

 

In 2023, BAT announced that it has refined its strategy, continuing to focus on the core vision of "building a smoke-free world" and aiming to achieve a revenue structure primarily focused on smoke-free business by 2035. The current number of users of new tobacco products is 29.1 million, accounting for 17.5% of the group's total revenue.

 

BAT emphasizes that driving transformation relies on precise execution, continuous product innovation, and responsibly meeting the preferences of adult consumers.

 

British American Tobacco (BAT) has stated that the promotion of new tobacco products should be based on harm reduction principles, and has pointed out that New Zealand and Sweden have already achieved or are close to achieving their "smoke-free" national goals. This demonstrates the positive results brought about by regulatory policies supporting harm reduction strategies.

 

According to BAT's warning, restrictive policies implemented by some countries may have unintended consequences, hindering adult smokers from transitioning to lower-risk alternative products. BAT is calling for enhanced policy dialogue based on scientific evidence, and has outlined five industry development goals through its regulatory position statement on e-cigarette products and the forthcoming release of "Omni™" (set to launch in London in September 2024 and internationally in 2025).

 

To prevent minors from accessing, including age verification through technological means; promote responsible packaging, marketing, and flavor use; strengthen product safety assessments; increase the recyclability of equipment, such as removable batteries; support effective market supervision and penalties for violations. BAT said it will continue to seek multi-party collaboration with policymakers, regulatory agencies, and public health organizations to promote the establishment of sustainable industry standards.

 

 

Deployment priorities and financial expectations for the year 2025

 

 

The year 2025 has been dubbed as the "year of deployment," as BAT plans to restore profit growth in the US market and continue to roll out product innovations. Full-year revenue is expected to increase by approximately 1%, with adjusted operating profit growth of 1.5%-2.5% (including a 1.5% headwind from foreign exchange trading). The second half of the year is expected to be the main driver of growth.

 

The exchange rate factor is expected to have a transformative impact of 2% on annual operating profit. BAT maintains its medium-term goal: from 2026 onwards, it aims to achieve annual revenue growth of 3%-5% and operating profit growth of 4%-6%.

 

In terms of cash flow, BAT expects to generate over £50 billion in free cash flow between 2024 and 2030, maintaining capital allocation discipline, including:

 

Continue investing in transformation; balance deleveraging, dividend growth, and share buybacks; selectively pursue small-scale mergers and acquisitions to accelerate the transformation process. BAT has announced a 2% increase in dividends by 2025 and will implement a £9 billion share buyback.

 

Since the last shareholders' meeting, there have been changes to the board of directors. Soraya Benchikh was appointed as Chief Financial Officer and Director in May 2024, while in February 2025, Uta Kemmerich-Keil joined the board as an independent non-executive director and also joined the audit and nomination committee. Murray Kessler became a non-executive director in November 2024 but stepped down in February 2025 to focus on his recent appointment as CEO of Wellington International LLC.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Drug Regulator Target Illegal Vape Sales Disguised as Medical Devices, Define Six Violations
China’s Jiangsu Tobacco Monopoly Bureau and Jiangsu Provincial Medical Products Administration have issued a joint notice targeting illegal production and sales of vape products disguised as medical devices. The notice identifies six categories of violations, including obtaining medical licenses through false materials, misusing medical device credentials, expanding production beyond approved scopes, and using medical device-related online platforms to promote or sell vape products. The action is based on China’s tobacco and medical device regulations and aims to strengthen vape oversight and consumer protection.
Aug.04
U.S. Appeals Court Says BAT Must Face Class Action Over Cigarette Labels
U.S. Appeals Court Says BAT Must Face Class Action Over Cigarette Labels
A U.S. appeals court ruled that British American Tobacco (BAT) must continue facing a consumer class action lawsuit over cigarette labels. The ruling allows the case to proceed but does not determine that BAT violated the law or is liable for damages. The case highlights ongoing legal risks facing major tobacco companies related to product labeling, consumer disclosures and product liability claims.
Jul.31
BAT Calls for Retailer Input in Future Nicotine Regulations
BAT Calls for Retailer Input in Future Nicotine Regulations
British American Tobacco (BAT) has called for stronger retailer involvement in shaping future nicotine product regulations in the UK, arguing that frontline market feedback should be considered during policy development. BAT said retailers provide direct insight into consumer behavior, market changes and regulatory implementation challenges. The comments come as the UK nicotine market undergoes regulatory changes, including the disposable vape ban, Vaping Products Duty and efforts to address illicit vape sales.
Jul.29
China’s HTP Exports Fell 14.3% in H1 2026 as Russia and Belarus Accounted for 76% Lead
China’s HTP Exports Fell 14.3% in H1 2026 as Russia and Belarus Accounted for 76% Lead
In H1 2026, China’s HS 24041100 exports stood at $1.32 million, down 14.3% YoY, with volume falling 17.2% to 55.33 tons. Market distribution shifted drastically amid overall export drops. Exports to Russia and Belarus totaled $1 million, taking 76.0% of all shipments versus 29.5% in H1 2025. Belarus became the top destination with export value jumping 177.5%, while the Philippines, Singapore and Indonesia’s combined share slumped from 49.3% to 11.2%.Domestically, Yunnan led exporter registrations; Jiangsu and Shanghai were key suppliers, yet Anhui and Sichuan had no exports. Heavy concentration means order or declaration changes for Russia/Belarus greatly affect national aggregate data. The data shows customs entry points (not end markets), covering tobacco consumables only, excluding heating equipment and the complete HTP supply chain.
Aug.11
Italy and Greece Oppose Ireland’s Nicotine Product Bill, Raising EU Regulatory Concerns
Italy and Greece Oppose Ireland’s Nicotine Product Bill, Raising EU Regulatory Concerns
Italy and Greece have opposed Ireland’s proposed nicotine product regulations, arguing that the measures could affect EU market coordination and the free movement of products. Ireland plans to introduce stricter rules covering nicotine products including vapes and nicotine pouches, with measures involving packaging, marketing and sales controls. The dispute highlights differences among EU member states between stronger public health protections and maintaining regulatory consistency within the bloc’s single market.
Jul.29
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
Oral Thin-Film Technology Firm CTT Pharma Eyes U.S. Nicotine Product Trials
CTT Pharmaceutical Holdings said it has signed a letter of intent with a U.S. company to conduct clinical trials and testing for several potential nicotine products using its patented oral thin-film technology.
Jun.18